To help address border security and ensure United States Border Patrol (USBP) agents can perform their job both safely and effectively, the Department of Homeland Security Science and Technology Directorate (S&T) recently collaborated with the USBP and the Federal Law Enforcement Training Centers to deliver a multi-part solution by implementing innovative tools and capabilities that enable USBP agents to leverage the knowledge, skills, and abilities of expert trackers and use emerging technologies to maximize their tracking performance.
The U.S. Department of Health and Human Services (HHS) will partner with Cytovale of San Francisco, to advance the development of a test that may be able to diagnose sepsis in less than 10 minutes. Sepsis could pose an even greater health security threat in a chemical, biological, radiological or nuclear emergency, or as a complication of an influenza pandemic or other emerging infectious disease outbreak.
With the very real possibility of a chemical attack in public, the United States needs to be prepared to take appropriate action to save lives. The Department of Homeland Security Science and Technology Directorate has developed a suite of models to help federal agencies analyze threats, vulnerabilities, and consequences of potential attacks to prioritize resources for the most effective defense and response.
A new Global Health Security (GHS) Index, the first comprehensive assessment and benchmarking of health security and related capabilities across 195 countries, suggests that not a single country in the world is fully prepared to handle an epidemic or pandemic. The inaugural GHS Index finds severe weaknesses in countries’ abilities to prevent, detect, and respond to significant disease outbreaks.
Researchers in Lincoln Laboratory's Chemical and Biological Technologies Group and Advanced Materials and Microsystems Group are using a color-changing technique while developing a self-reading "pH fabric" that could help warn of dangerous chemical releases. This technology could help address the evolving threat of chemical releases, including those from industrial incidents or terrorist attacks.
A new effort is underway to tap a powerful yet under-leveraged technology that will provide government officials and utilities with the first-ever near real time, automated warning when emergency power is threatened at a hospital or other critical healthcare facility grappling with an extended power outage.
This early warning of a threat to emergency power will be provided through the Power P.I.O.N.E.E.R. Dashboard.
FLIR Systems Inc. announced the launch of the FLIR identiFINDER® R425, the next-generation of its field-trusted R400 handheld radionuclide identification device. The identiFINDER R425 provides responders with increased sensitivity, flexible power management, and advanced communication features that enable them to safely locate and measure radioactive sources with confidence.
According to the National Highway Traffic Safety Administration, nearly six million Americans are involved in a car accident annually, including 60,000 first responders. In an effort to reduce first responder related crashes, the Department of Homeland Security Science and Technology Directorate is collaborating with “HAAS Alert,” a Chicago-based company developing and standardizing C-V2X (cellular vehicle-to-everything) technology that enables emergency response vehicles to send real-time digital alerts to supplement their lights and sirens.
The Biomedical Advanced Research and Development Authority (BARDA) is proud to have established unique partnerships with industry that create solutions for the American people. By working together, they have earned their 50th and 51st U.S. Food and Drug Administration (FDA) approvals, licensures, and clearances in the past 12 years for products that address some of the nation’s most challenging health security threats.
The U.S. Food and Drug Administration (FDA) allowed marketing of a rapid diagnostic test to detect Ebola virus antigens (proteins) in human blood from certain living individuals and samples from certain recently deceased individuals suspected to have died from Ebola. The OraQuick Ebola Rapid Antigen Test is the first rapid diagnostic test the FDA has allowed to be marketed in the United States for the Ebola Virus Disease.